IgE and IgG4 Epitopes of Dermatophagoides and Blomia Allergens before and after Sublingual Immunotherapy

Imagem de Miniatura
Arquivos
art_FIGO_IgE_and_IgG4_Epitopes_of_Dermatophagoides_and_Blomia_.PDF (2.4 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
GADERMAIER, Gabriele
Citação
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.24, n.4, article ID 4173, 16p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Sublingual immunotherapy (SLIT) is used worldwide to treat house dust mites (HDM) allergy. Epitope specific immunotherapy with peptide vaccines is used far less, but it is of great interest in the treatment of allergic reactions, as it precludes the drawbacks of allergen extracts. The ideal peptide candidates would bind to IgG, blocking IgE-binding. To better elucidate IgE and IgG4 epitope profiles during SLIT, sequences of main allergens, Der p 1, 2, 5, 7, 10, 23 and Blo t 5, 6, 12, 13, were included in a 15-mer peptide microarray and tested against pooled sera from 10 patients pre- and post-1-year SLIT. All allergens were recognized to some extent by at least one antibody isotype and peptide diversity was higher post-1-year SLIT for both antibodies. IgE recognition diversity varied among allergens and timepoints without a clear tendency. Der p 10, a minor allergen in temperate regions, was the molecule with more IgE-peptides and might be a major allergen in populations highly exposed to helminths and cockroaches, such as Brazil. SLIT-induced IgG4 epitopes were directed against several, but not all, IgE-binding regions. We selected a set of peptides that recognized only IgG4 or were able to induce increased ratios of IgG4:IgE after one year of treatment and might be potential targets for vaccines.
Palavras-chave
IgE, IgG, house dust mites, immunotherapy, epitopes
URI
https://observatorio.fm.usp.br/handle/OPI/52837
Referências
  1. Akdis CA, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0063-2
  2. Calzada D, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13071007
  3. Carnes J, 2017, ANN ALLERG ASTHMA IM, V118, P249, DOI 10.1016/j.anai.2016.08.018
  4. Chen JJ, 2016, J ALLERGY CLIN IMMUN, V137, pAB401, DOI 10.1016/j.jaci.2015.12.1244
  5. Chinthrajah RS, 2019, LANCET, V394, P1437, DOI 10.1016/S0140-6736(19)31793-3
  6. Cui YB, 2016, IUBMB LIFE, V68, P792, DOI 10.1002/iub.1540
  7. Curin M, 2018, ALLERGY, V73, P1653, DOI 10.1111/all.13398
  8. Curin M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687294
  9. da Silva ES, 2017, INT ARCH ALLERGY IMM, V172, P203, DOI 10.1159/000464325
  10. DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802
  11. Du ZY, 2021, NAT PROTOC, V16, P5634, DOI 10.1038/s41596-021-00628-9
  12. Durham SR, 2022, NAT REV IMMUNOL, DOI 10.1038/s41577-022-00786-1
  13. Ebrahimi N, 2019, MOL CELL PROBE, V46, DOI 10.1016/j.mcp.2019.05.004
  14. Elenburg S, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-24
  15. Feng ML, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00030
  16. Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x
  17. Gellrich D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63087-4
  18. GREENE WK, 1991, J IMMUNOL, V147, P3768
  19. Guilleminault L, 2017, REV MAL RESPIR, V34, P791, DOI 10.1016/j.rmr.2016.10.877
  20. Hoffmann-Sommergruber K., PEDIAT ALLERG IMM-UK, P2023, DOI [10.1111/all.15643, DOI 10.1111/ALL.15643]
  21. Holm J, 2011, J ALLERGY CLIN IMMUN, V127, P1029, DOI 10.1016/j.jaci.2011.01.062
  22. Huber S, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0226-7
  23. Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x
  24. Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047
  25. Kobayashi I, 1996, J ALLERGY CLIN IMMUN, V97, P638, DOI 10.1016/S0091-6749(96)70309-3
  26. Lahiani S, 2018, PROTEIN PEPTIDE LETT, V25, P1024, DOI 10.2174/0929866525666181114144635
  27. Lahiani S, 2019, INT ARCH ALLERGY IMM, V178, P10, DOI 10.1159/000492871
  28. Li WY, 2022, WORLD ALLERGY ORGAN, V15, DOI 10.1016/j.waojou.2022.100651
  29. LOMBARDERO M, 1990, J IMMUNOL, V144, P1353
  30. Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030
  31. Mikus M, 2021, J ALLERGY CLIN IMMUN, V147, P1077, DOI 10.1016/j.jaci.2020.08.002
  32. Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x
  33. Mueller GA, 2020, J IMMUNOL, V205, P1999, DOI 10.4049/jimmunol.2000295
  34. Mukonyora M., 2015, J CLIN CELL IMMUNOL, V6, P1, DOI [10.4172/2155-9899.1000358, DOI 10.4172/2155-9899.1000358]
  35. Munera M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246107
  36. Niederberger V, 2018, J ALLERGY CLIN IMMUN, V142, P497, DOI 10.1016/j.jaci.2017.09.052
  37. Nittner-Marszalska M, 2022, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2022.2148815
  38. Orengo JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03636-8
  39. Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x
  40. Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
  41. Pomes A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02067
  42. Ramos JDA, 2003, CLIN EXP ALLERGY, V33, P511, DOI 10.1046/j.1365-2222.2003.01623.x
  43. Rauber MM, 2020, ALLERGY, V75, P450, DOI 10.1111/all.13996
  44. Resch Y, 2011, CLIN EXP ALLERGY, V41, P1468, DOI 10.1111/j.1365-2222.2011.03798.x
  45. Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1
  46. Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147
  47. Savilahti EM, 2014, PEDIAT ALLERG IMM-UK, V25, P227, DOI 10.1111/pai.12186
  48. Sousa-Santos ACAF, 2020, INT ARCH ALLERGY IMM, V181, P221, DOI 10.1159/000504982
  49. Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299
  50. VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9
  51. Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048
  52. Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
  53. Westritschnig K, 2003, CLIN EXP ALLERGY, V33, P22, DOI 10.1046/j.1365-2222.2003.01540.x
  54. Wraith DC, 2021, CLIN EXP ALLERGY, V51, P751, DOI 10.1111/cea.13840
  55. Yang L, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.786738
  56. Yi FC, 2004, CLIN EXP ALLERGY, V34, P1762, DOI 10.1111/j.1365-2222.2004.02107.x
  57. Yi FC, 2002, CLIN EXP ALLERGY, V32, P1203, DOI 10.1046/j.1365-2745.2002.01449.x
  58. Yukselen A, 2013, ASIAN PAC J ALLERGY, V31, P233, DOI 10.12932/AP0276.31.3.2013

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03